$RYTM

Palatin Technologies (PTN), valued at $20M, is developing melanocortin-receptor drugs for rare obesity, following Rhythm Pharmaceuticals (RYTM) and Neurocrine Biosciences' successes in the space. PTN's programs aim to improve efficacy and tolerability, with clinical trials expected to start in late 2026 and 2027. The market's validation of MC4R targets and rare-obesity drugs could significantly impact PTN's valuation.

Meeker David P (President and CEO) sold 50,000 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at an average of $102.67 ($101.75–$105.19, $5.13M total) across 5 trades on 2026-09-14 under a Rule 10b5-1 trading plan.

Rhythm Pharmaceuticals (RYTM) received an 'Outperform' rating and $133 price target from Leerink Partners. The company's GF Value™ suggests it is 17.3% undervalued at $102.44, but insiders have sold $27.38M in shares. RYTM focuses on rare neuroendocrine diseases, with a market cap of $7.05B. Its GF Score™ is 57, indicating moderate performance.

Rhythm Pharmaceuticals (RYTM) insider David Meeker filed a Rule 144 notice to sell 50,000 shares, valued at $5.24M, acquired via option exercise on or after September 14, 2026, through Morgan Stanley.

Rhythm Pharmaceuticals (RYTM) presented new data at the 64th ESPE Meeting, showing positive results for setmelanotide in treating paediatric acquired hypothalamic obesity, including BMI reductions and improved metabolic indices. Analysts note this strengthens the company's clinical story but does not alter its near-term financial losses. The data may support future regulatory and reimbursement progress, with analysts projecting significant revenue growth by 2029.

Rhythm Pharmaceuticals (RYTM) presented data at ESPE 2026 showing setmelanotide reduced BMI and improved cardiometabolic markers in paediatric hypothalamic obesity patients. Real-world data from France showed mean BMI reductions of 11.5% at 6 months and 9.0% at 18 months. Phase 3 analyses showed significant improvements in metabolic indices compared to placebo.

Smith Hunter C (Chief Financial Officer) sold 62,774 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at an average of $105.46 ($104.59–$106.20, $6.62M total) across 3 trades on 2026-08-31 under a Rule 10b5-1 trading plan.

Rhythm Pharmaceuticals (RYTM) officer Hunter Smith filed a Rule 144 notice to potentially sell 57,187 shares from stock options and 5,587 shares from restricted stock units. The sales are not yet completed, with Morgan Stanley Smith Barney LLC as the broker.

Rhythm Pharmaceuticals (RYTM) has outperformed the market over the past 5 years, with an annualized return of 52.06%. A $100 investment 5 years ago would be worth $782.75 today. The company has a market capitalization of $7.42 billion.

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.